STMN1 (phospho-Ser25) Antibody
- Known as:
- STMN1 (phosphorilated-Ser25) Antibody
- Catalog number:
- abx000272
- Product Quantity:
- EUR
- Category:
- -
- Supplier:
- Abbexa
- Gene target:
- STMN1 (phospho-Ser25) Antibody
Related genes to: STMN1 (phospho-Ser25) Antibody
- Gene:
- STMN1 NIH gene
- Name:
- stathmin 1
- Previous symbol:
- LAP18, C1orf215
- Synonyms:
- SMN, OP18, PR22, PP19, PP17, Lag, FLJ32206
- Chromosome:
- 1p36.11
- Locus Type:
- gene with protein product
- Date approved:
- 1990-12-17
- Date modifiied:
- 2014-11-19
Related products to: STMN1 (phospho-Ser25) Antibody
Related articles to: STMN1 (phospho-Ser25) Antibody
- Gastric cancer is a heterogeneous disease in which cancer stem cell-associated properties may contribute to tumor heterogeneity and progression. This study aimed to establish paired normal and tumor gastric organoids, characterize stemness-related gene expression, and explore its association with organoid formation. - Source: PubMed
Publication date: 2026/08/31
Yoo Yie-RiJeong KyoungyunYoo JaeunKim Hyun MyongShin Ji-YeonKang Min KyuPark KyoyoungKim Sa-HongKim ChungyoonKim JeesunPark Young SukKong Seong-HoLee Hyuk-JoonYang Han-KwangPark Do Joong - Glioblastoma (GBM) is among the most aggressive primary brain tumors, marked by rapid proliferation, therapeutic resistance, and profound intratumoral heterogeneity. Epigenetic regulators such as lysine-specific demethylase 1A (KDM1A) and histone deacetylase 2 (HDAC2) are aberrantly expressed in resistant GBM subpopulations and strongly correlate with poor clinical outcomes. Here, we assessed the therapeutic potential of MPT0G521, a dual KDM1A/class I HDAC inhibitor, in disrupting epigenetic regulation and cell cycle progression. Bioinformatic analyses of resistance-associated gene profiles (temozolomide and 2 Gy radiation) and single-cell transcriptomic datasets from distinct tumor regions revealed enrichment of KDM1A and HDAC2 in high-cycling GBM clusters, particularly at invasive margins prone to recurrence. Functional assays demonstrated that MPT0G521 potently inhibited proliferation of both parental and temozolomide-resistant GBM cells, inducing G2/M arrest and apoptosis. Transcriptomic profiling further identified significant downregulation of centrosome integrity genes (FSD1, KIFC1), spindle regulators (TUBB, STMN1, KIF2C, KIF15), kinetochore components (AURKB, CDCA8, SPAG5), and G2/M checkpoint mediators (CENPF, MYBL2, CCNF, MYT1, CDC25A), resulting in disrupted mitotic progression. Mechanistically, MPT0G521 increased histone H3 methylation and acetylation, validating its dual inhibitory activity against KDM1A and class I HDACs. Collectively, these findings indicate that MPT0G521 disrupts the G2/M activation and mitotic machinery, thereby suppressing proliferative and resistant GBM subpopulations. This dual epigenetic strategy holds strong promise for overcoming GBM heterogeneity and reducing recurrence. - Source: PubMed
Publication date: 2026/09/02
Wu An-ChihChuang Jian-YingLiu Jr-JiunSalim Enrica AngelinaWu Ming-HsiaoJing Shih-WeiHsu Tsung-IChang Kwang-YuChang Wen-ChangThakur AmandeepLiou Jing-PingLo Wei-Lun - Skin is a highly specialized barrier organ, which serves essential barrier, immune, and sensory functions and exhibits conserved structure. In addition, each species exhibits a unique skin transcriptional profile for adapting distinct environmental conditions and physiological demands. However, these transcriptional profiles across mammals remain incompletely understood. In this study, we integrated 61 publicly available skin RNA-seq datasets from eight mammalian species: human (), macaque (), mouse (), sheep (), goat (), donkey (), rabbit (), and pig (). We identified a large number (2286 to 4588) of differentially expressed genes (DEGs) based on 10,504 one-to-one orthologous genes in all pairwise species comparisons. A total of 44 conserved genes were identified by integrating tissue specificity, expression variability, and mean expression level, which were enriched in epidermal development, keratinocyte differentiation, and desmosome organization. We also identified species-specific genes and transcription factors, such as (donkey), (goat), and (mouse), which are associated with the cell cycle, extracellular matrix, and muscle contraction pathways, respectively. WGCNA further revealed goat-associated module 2 (M2) enriched in the negative regulation of angiogenesis. Collectively, this study provides a comprehensive cross-species transcriptional profile resource for mammalian skin, providing a valuable resource for understanding the regulatory plasticity underlying skin evolution across mammals. - Source: PubMed
Publication date: 2026/08/21
Wei Wen-TianZhou ChenHuang Qi-XuanNing Zhong-HuaBai Yi-LinBai Yue-YuXu Song-Song - Stathmin 1 (STMN1) is a cytosolic phosphoprotein involved in microtubule dynamics, mitotic progression and cytoskeleton-dependent cellular behaviour. In multiple human malignancies, dysregulated STMN1 expression has been associated with aggressive clinicopathological features, adverse outcomes and, in selected settings, potential therapeutic vulnerability. Its significance in neuroendocrine neoplasms (NENs), however, has not been critically synthesised across anatomical sites. This narrative review examined the available literature on STMN1 in NENs across pulmonary, gastroenteropancreatic, adrenal, cutaneous, pituitary and thyroid settings, with the specific aim of mapping site-specific expression patterns and appraising whether reported associations with aggressive clinicopathological features were descriptive, independently validated, or functionally supported. A literature search was conducted in PubMed, Web of Science, and Scopus from inception to 25 January 2026. Twelve original studies met the inclusion criteria and were narratively synthesised. The available evidence indicates that STMN1 is not a uniform marker of neuroendocrine differentiation across tumour types, but rather a context-dependent signal more often associated with proliferative activity, high-grade morphology and malignant behaviour. The strongest evidence currently derives from pulmonary neuroendocrine neoplasms, where STMN1 has shown diagnostic utility in tissue and bronchoalveolar lavage and where preclinical targeting data are available. Outside the lung, however, the literature is limited and methodologically heterogeneous, and the evidentiary weight varies from descriptive expression studies to functional preclinical observations. Overall, STMN1 emerges as a recurrent molecular signal in several NEN settings, particularly in aggressive and high-grade disease contexts. Its causal biological relevance and clinical value, including potential implications for treatment sensitivity and tumour dissemination, remain to be demonstrated in studies specifically designed for prognostic and therapeutic validation. Current therapeutic evidence remains preclinical and should be regarded as hypothesis-generating rather than clinically actionable. - Source: PubMed
Publication date: 2026/08/06
La Salvia AnnaTanca AlessandroGaudenzi GermanoPecora GiuliaFaggiano AntongiulioVitale GiovanniCossu-Rocca PaoloFanciulli Giuseppe - The prognostic role of STMN1 and its regulatory effects on the tumor microenvironment (TME) in biliary tract cancer (BTC) remain poorly defined. This study aimed to investigate the prognostic value of STMN1 and its predictive capacity for chemotherapy and immunotherapy responses among patients with BTC. - Source: PubMed
Publication date: 2026/07/20
Wang ChangchengNan LingxiMeng QingyangLu ChengjiaCui WenkaiSuo TaoZhang ShulongLiu HoubaoWang YueqiQiu WenqingBo Xiaobo